Skip to main content
. Author manuscript; available in PMC: 2021 Sep 22.
Published in final edited form as: Oncogene. 2021 Jul 16;40(35):5379–5392. doi: 10.1038/s41388-021-01914-2

Figure 6.

Figure 6.

ARVib improves enzalutamide treatment in vitro and in vivo. A-B. CWR22Rv1 cells were treated with DMSO, 20 ¼M enzalutamide, 0.5 ¼M ARVibs or their combination. Cell growth was determined at 3 days and colony formation ability was examined by clonogenic assay. C. Mice bearing VCaP xenografts were castrated and the relapsed tumors were treated with vehicle control, enzalutamide (25 mg per Kg p.o), ARVib-7 (75 mg per Kg p.o.) or their combination for 24 days (n=8). Tumor volumes were measured twice weekly. D. Tumors were photographed. Scale bar 1 cm. Data represent means ±S.D. from 8 mice per group. E. Tumors weight. F. PSA expression in mice serum was examined. G. Kaplan-Meier curves showing survival benefits of ARVib-7 single treatment, ARVib-7 and enzalutamide combination treatment in relapsed VCaP tumors. H. Body weight was determined. I. IHC staining of Ki67, AR-V7 and HSP70 in each group was performed and quantified.* p<0.05.